Does systemic treatment of psoriasis reduce the risk of comorbidities?

In this issue of the BJD, Neil Korman has published an interesting review article presenting the evidence supporting psoriasis as a systemic disease. He also discusses new psoriasis treatment paradigms, which may potentially reduce the effects of systemic inflammation and consequently prevent or reverse comorbidities.1 Optimizing patient outcomes beyond clearing the skin, such as reducing the risk of cardiovascular diseases, is crucially relevant for our clinical practice. In this commentary, the pathogenesis behind the comorbidities and whether systemic treatment of psoriasis could reduce the risk of comorbidities by damping systemic inflammation will be discussed.